Literature DB >> 3183883

Localized intestinal perforation following intravenous indomethacin for patent ductus arteriosus.

T D Scholz1, G A McGuinness.   

Abstract

We describe a very low birth weight infant given intravenous indomethacin for a symptomatic patent ductus arteriosus who subsequently developed a gastrointestinal perforation. Although this is a well-known complication of enteral preparations, it has not been described with the intravenous form. Various mechanisms described in the literature by which the intravenous route of administration may compromise the bowel are presented. Although rare, gastrointestinal complications with intravenous indomethacin may become more prevalent with its increased use.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183883     DOI: 10.1097/00005176-198809000-00026

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

Review 1.  Pathology of drug-associated gastrointestinal disease.

Authors:  Ashley B Price
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

2.  Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.

Authors:  R C Coombs; M E Morgan; G M Durbin; I W Booth; A S McNeish
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 3.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

4.  Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.

Authors:  Rajan Wadhawan; William Oh; Betty R Vohr; Shampa Saha; Abhik Das; Edward F Bell; Abbott Laptook; Seetha Shankaran; Barbara J Stoll; Michele C Walsh; Rose Higgins
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-06-09       Impact factor: 5.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.